Detalhe da pesquisa
1.
Integrative clinical genomics of advanced prostate cancer.
Cell
; 161(5): 1215-1228, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26000489
2.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37844613
3.
Integrative Clinical Genomics of Advanced Prostate Cancer.
Cell
; 162(2): 454, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843286
4.
Bench to Bedside Development of [18F]Fluoromethyl-(1,2-2H4)choline ([18F]D4-FCH).
Molecules
; 28(24)2023 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38138508
5.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(1): 162-174, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806540
6.
Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).
Int J Cancer
; 143(10): 2584-2591, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30006930
7.
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
Hum Mol Genet
; 25(24): 5490-5499, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27798103
8.
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
N Engl J Med
; 373(18): 1697-708, 2015 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26510020
9.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Eur J Cancer
; 205: 114103, 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729054
10.
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
Oncogene
; 42(12): 926-937, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725887
11.
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
Science
; 374(6564): 216-224, 2021 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34618582
12.
HER3 Is an Actionable Target in Advanced Prostate Cancer.
Cancer Res
; 81(24): 6207-6218, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34753775
13.
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
BJU Int
; 103(9): 1256-69, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19040532
14.
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Eur Urol
; 76(5): 676-685, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036442
15.
Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles.
Cancers (Basel)
; 10(11)2018 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30384500
16.
Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.
Oncotarget
; 9(27): 19283-19293, 2018 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29721202
17.
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Eur Urol
; 74(3): 283-291, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29500065
18.
A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.
PLoS One
; 13(3): e0193689, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29494651
19.
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.
Clin Cancer Res
; 24(22): 5635-5644, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093450
20.
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Cancer Discov
; 7(9): 1006-1017, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28450425